US drug regulators have turned down Ipsen's effort to slow down generic competition for its blockbuster drug Somatuline Depot ...

Marketresearch.biz reports that the Somatostatin Analogs Market size is expected to be worth around USD 11.4 Billion by 2033, ...

Market OverviewThe Global Medical Panel PC Market is projected to experience steady growth over the next decade, expanding from USD 292 Million in 2023 to an estimated USD 396 Million by 2033. This ...

The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.

Drugmaker Cipla on Wednesday announced that the US Food and Drug Administration (USFDA) has granted it final approval for the ...

Cipla, a major pharmaceutical company, has obtained approval from the US Food and Drug Administration (FDA) to market its ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...

The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic ...

Mumbai-headquartered pharma major Cipla US arm has secured final approval from the United States Food and Drug Administration USFDA for its Lanreotide Inje ...

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used ...

Cipla's Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic ...

The wholly-owned subsidiary Cipla USA Inc has received the final approval for the Abbreviated New Drug Application (ANDA) of ...